Neuraxis cuts Flagstaff investment to $1.8M, raises $145k from new Series B preferred sale

Neuraxis, INC

Fourth Amendment reduces Flagstaff SPA total from $5M to $1.8M; $800k received, $1M due by Dec 31, 2024.
New SPAs with multiple investors for 60,924 Series B Preferred shares at $2.38/share, aggregate $145k.
Series B Preferred convertible into common at any time; dividend/liquidation rights expire June 30, 2025.
Proceeds from the new SPAs to be used for working capital and general corporate purposes.
Flagstaff SPA termination terms revised; automatic upon full payment or breach with cure through Jan 9, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.